Galantamine: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Galantamine/Galantamine/2" align="right" caption="Tacrine, also known as Cognex"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Galantamine/Galantamine/2" align="right" caption="Tacrine, also known as Cognex"/> | ||
===Better Known as: Razadyne=== | ===Better Known as: Razadyne=== | ||
* Marketed By: <br /> | * Marketed By: Ortho Mcneil Janssen Pharmaceuticals (Subsidiary of Johnson & Johnson)<br /> | ||
* Major Indication: [[Alzheimer's Disease]]<br /> | * Major Indication: [[Alzheimer's Disease]]<br /> | ||
* Drug Class: [[Acetylcholinesterase]] Inhibitor | * Drug Class: [[Acetylcholinesterase]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): <br /> | * Date of FDA Approval (Patent Expiration): 2001 (2008) <br /> | ||
* 2006 Sales: $225 Million<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | * 2006 Sales: $225 Million<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | ||
* Importance: | * Importance: Part of a newer generation of treatments for [[Alzheimer's Disease]], although no definitive proof exists as to whether it alters the progression of the disease. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||
